A fast, accurate, sensitive, selective and reliable method using reversed-phase high-performance liquid chromatography-mass spectrometry coupling with an electrospray ionization interface was developed and validated for the determination of finasteride in human plasma. After deprotienation with acetonitrile, centrifugation, evaporation to dryness and dissolving in mobile phase, satisfactory separation was achieved on a Hypersil-Keystone C(18) reversed-phase column using a mobile phase consisting of acetonitrile-water (46:54, v/v), 0.1% acetic acid and 0.1% trifluoracetic acid. Carbamazepine (IS) was used as internal standard. This method involved the use of the [M+H](+) ions of finasteride and IS at m/z 373 and 237 with the selective ion monitoring (SIM) mode. The calibration curve was linear in the range of 0.2-120 ng ml(-1). The limit of quantification for finasteride in plasma was 0.2 ng ml(-1) with good accuracy and precision. The intra-assay precision and accuracy were in the range of 2.1-11.2% and -1.3% to 8.5%, respectively. The inter-assay precision and accuracy were in the order of 3.4-12.1% and -1.5% to 11.5%, respectively. The mean sample extract recoveries of the method were higher than 85% and 74% for finasteride and internal standard (IS), respectively. The assay has been successfully used to estimate the pharmacokinetics of finasteride after oral administration of a 5mg tablet of finasteride to 24 healthy volunteers.
[Show abstract][Hide abstract] ABSTRACT: Finasteride in hydroalcoholic solutions (ethanol/Britton-Robinson buffer, 30/70) exhibits cathodic response in a wide range of pH (-0.5 to 12) using differential pulse (DPP) and test polarography (TP). The reduction peak of finasteride at acidic pH, is a catalytic proton peak resulting from a mechanism involving a first protonation of finasteride followed by the reduction of the protons combined with finasteride in order to regenerate finasteride and liberate hydrogen. Based on the catalytic hydrogen wave, a novel method for the determination of finasteride can be proposed. For analytical purposes we selected DPP technique in an ethanol/0.0625 mol L(-1) H(2)SO(4) (30/70) solution medium. In this condition the I(p) varied linearly with finasteride concentration between 5 x 10(-5) and 5 x 10(-4) mol L(-1). Within-day and inter-day reproducibility's were adequate with R.S.D. values lower than 2%. The selectivity of the method was checked with both accelerated degradation trials and typical excipients formulations. The developed method was applied to the assay and the uniformity content of finasteride tablets and compared with the standard HPLC method. The DPP-developed method was adequate for the finasteride determination in pharmaceutical forms as that exhibited an adequate accuracy, reproducibility and selectivity. Furthermore, treatment of the sample was not required as in HPLC; the method is not time-consuming and less expensive than the HPLC ones.
[Show abstract][Hide abstract] ABSTRACT: Reversed-phase high-performance liquid chromatography (RP-HPLC) and thin-layer chromatography (TLC) methods have been developed and validated for simultaneous estimation of tamsulosin hydrochloride and finasteride in bulk drug and in combined dosage forms. RP-HPLC separation was achieved on a Phenomenex C18 column using methanol/0.02 mol L-1 ammonium acetate buffer/triethylamine (79.9 + 20 + 0.1, V/V/V) (pH 9.2) as mobile phase. TLC separation was achieved on an aluminium-backed layer of silica gel 60 F254 using toluene/methanol/triethylamine (9 + 1.5 + 1, V/V/V) as eluent. Quantification was achieved with photodiode array (PDA) detection at 235 nm over the concentration range 0.5-16 and 1-50 μg mL-1 with mean recovery of 99.8 ± 0.9 and 100.0 ± 0.8% for tamsulosin hydrochloride and finasteride, respectively, by the RP-HPLC method. Quantification was achieved with UV detection at 270 nm over the concentration range 100-2000 ng per spot and 250-5000 ng per spot with mean recovery of 98.9 ± 0.9 and 99.6 ± 0.7 % for tamsulosin hydrochloride and finasteride, respectively, by the TLC method. Both methods are simple, precise, accurate and sensitive and are applicable to the simultaneous determination of tamsulosin hydrochloride and finasteride in bulk drug and in combined dosage forms.
[Show abstract][Hide abstract] ABSTRACT: A rapid, specific, and sensitive method utilizing reversed-phase ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) was developed and validated to determine finasteride levels in human plasma. The plasma samples were prepared by liquid-liquid extraction with ethyl acetate, evaporation, and reconstitution. MS/MS analyses were performed on a triple-quadrupole tandem mass spectrometer by monitoring protonated parent-->daughter ion pairs at m/z 373-->305 for finasteride and m/z 237-->194 for carbamazepine (internal standard, IS). The method was validated with respect to linearity, recovery, specificity, accuracy, precision, and stability. The method exhibited a linear response from 0.1 to 30 ng/mL (r(2)>0.998). The limit of quantitation for finasteride in plasma was 0.1 ng/mL. The relative standard deviation (RSD) of intra- and inter-day measurements was less than 15% and the method was accurate within -6.0% to 2.31% at all quality-control levels. The mean extraction recovery was higher than 83% for finasteride and 84% for the IS. Plasma samples containing finasteride were stable under the three sets of conditions tested and the processed samples were stable up to 29 h in an autosampler at 5 degrees C. Detection and quantitation of both analytes within 3 min make this method suitable for high-throughput analyses. The method was successfully applied to a pharmacokinetic study of finasteride in healthy volunteers following oral administration.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 06/2010; 878(20):1718-23. DOI:10.1016/j.jchromb.2010.04.029 · 2.73 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.